Mild Cognitive Impairment Market Size

Global Mild Cognitive Impairment Market Overview

Mild Cognitive Impairment Market Size was valued at USD 1.94 Billion in 2023. The Global Mild Cognitive Impairment industry is projected to grow from USD 2.05 Billion in 2024 to USD 3.25 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.95% during the forecast period (2024 - 2032).

The increasing prevalence of mild cognitive impairment across the globe and rising awareness associated with mild cognitive impairment are the major factors driving the growth of the Mild Cognitive Impairment Market. However, polypharmacy and managing comorbidities complicate treatment strategies, which is expected to hamper the growth of the global market. Nevertheless, technological advancements for early diagnosis of MCI across the globe are anticipated to create lucrative opportunities for the market.

Mild Cognitive Impairment Market Trends

• Increasing burden of mild cognitive impairment across the globe fuels market growth

The increasing prevalence of mild cognitive impairment (MCI) globally is serving as a significant catalyst for the expansion of the global MCI treatment market. For instance, in October 2023, the University of Southern California (US) reported that approximately eight million Americans are suffering from mild cognitive impairment. Furthermore, in January 2024, CORDIS revealed that more than 10 million Europeans show MCI. Also, in March 2022, Karolinska Institute stated that more than one fourth of the older population in rural China was affected by MCI. Moreover, one of the major factors contributing to mild cognitive impairment is the growing geriatric population. As per the Alzheimer’s Association 2022 report, nearly 12% to 18% of people aged 60 or older are living with MCI in America. According to the World Population Prospects 2022, the population over the age of 65 is growing faster than the population under that age. Hence, the increasing MCI cases contributed to the increase in the burden of MCI, boosting the demand for treatment interventions across the globe and thus burgeoning the Mild Cognitive Impairment Market.

Mild Cognitive Impairment Market Segment Insights

Mild Cognitive Impairment Market Disease Type Insights

The Mild Cognitive Impairment Market segmentation, based on disease type, amnestic MCI and non-amnestic MCI. The amnestic MCI segment dominated the market in 2022 and is projected to be the fastest-growing during the forecast period, 2023–2032. Amnestic Mild Cognitive Impairment (MCI) is a subtype of MCI characterized by memory deficits beyond what is expected for a person's age but not severe enough to meet the criteria for dementia. Individuals with amnestic MCI typically exhibit memory impairment that is greater than expected for their age and educational level but do not show significant impairments in other cognitive domains such as language, executive function, or visuospatial skills. Amnestic MCI is considered a transitional stage between normal aging and dementia, particularly Alzheimer's disease. Research suggests that individuals with amnestic MCI have an increased risk of progressing to Alzheimer's disease or other forms of dementia compared to those without cognitive impairment.

Figure 2: Mild Cognitive Impairment Market, by Disease Type, 2023 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Mild Cognitive Impairment Market Age Insights

The mild cognitive impairment market segmentation, based on age, includes child, adult, and geriatric. The geriatric segment dominated the market in 2022 and adult is projected to be the fastest-growing during the forecast period, 2023–2032. Mild cognitive impairment (MCI) in geriatric individuals, particularly those aged 65 and older, is a common concern in clinical settings. For instance, Globally, the prevalence of cognitive impairment in individuals aged 50 years or older ranges from 5.1 to 41.0%, with a median of 19.0%. In children, mild cognitive impairment may manifest as difficulties in learning, memory, attention, executive functions, or language skills. Some potential causes include genetic factors, prenatal exposure to toxins or infections, perinatal complications, traumatic brain injury, neurodevelopmental disorders like autism spectrum disorder or attention deficit hyperactivity disorder (ADHD), and certain medical conditions affecting brain development.

Mild Cognitive Impairment Market Indication Insights

The Mild Cognitive Impairment Market has been segmented, based on indication into Lewy body dementia, Parkinson’s disease dementia, Alzheimer’s disease, vascular dementia, and others. The Alzheimer’s disease segment dominated the market in 2022 and Parkinson’s disease dementia is projected to be the fastest-growing during the forecast period, 2023–2032. Alzheimer's disease is a progressive neurodegenerative disorder that primarily affects memory, cognition, and behavior. It is the most common cause of dementia among older adults. For instance, more than 6 million Americans of all ages suffer with Alzheimer's disease. In 2023, an estimated 6.7 million Americans aged 65 and older were living with Alzheimer's. Seventy-three percent are aged 75 or older. Alzheimer's affects around one in every nine adults aged 65 and older (10.7%). Alzheimer's disease typically begins with subtle memory loss and progresses to include confusion, disorientation, and difficulty with language, reasoning, and problem-solving. Lewy body dementia (LBD) is a type of dementia characterized by the presence of abnormal protein deposits called Lewy bodies in the brain. These deposits disrupt the normal functioning of brain cells, leading to cognitive impairment, changes in behavior, and other symptoms. Cognitive impairment in LBD can manifest as difficulties with memory, reasoning, problem-solving, and other cognitive functions.

Mild Cognitive Impairment Market Treatment Insights

The Mild Cognitive Impairment Market has been segmented into medication and therapy. The medication segment dominated the market in 2022 and therapy is projected to be the fastest-growing during the forecast period, 2023–2032. Cognitive impairment can result from various underlying conditions such as Alzheimer's disease, vascular dementia, mild cognitive impairment, etc. Treatment options depend on the cause and severity of the impairment. Cognitive Stimulation Therapy (CST) is an evidence-based psychosocial intervention designed to improve cognitive function, quality of life, and well-being in people with cognitive impairment, particularly those with dementia. CST is typically delivered in a group format and involves a variety of activities and discussions aimed at stimulating cognitive abilities and social interaction. Cognitive Behavioral Therapy (CBT) has primarily been developed and utilized to treat various mental health conditions such as depression, anxiety disorders, and PTSD. However, there's been growing interest and some research in using CBT techniques to address cognitive impairment, particularly in populations like older adults or individuals with neurological conditions such as mild cognitive impairment (MCI) or dementia.

Mild Cognitive Impairment Market Regional Insights

By Region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World. North America mild cognitive impairment market accounted for the largest market share of 42.60% in 2022 and is anticipated to reach approximately USD 01.31 billion by 2032 at a 4.97% CAGR during the forecast period. However, Asia-Pacific is projected to grow at the highest CAGR of 6.91% during the forecast period. The outlook for the North America mild cognitive impairment market remains promising, with sustained growth anticipated. Investments in healthcare infrastructure and a growing awareness of advanced medical solutions are expected to drive market expansion further. Both established players and emerging entrants are poised to capitalize on these opportunities, leveraging technological advancements to meet the rising demand for improved surgical outcomes.

Further, the major countries will be study are US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: MILD COGNITIVE IMPAIRMENT MARKET BY REGION 2023 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe mild cognitive impairment market accounted for the second-largest market share due to technology advancements, increasing healthcare expenditure, and increasing burden of mild cognitive impairment. Furthermore, the Germany mild cognitive impairment market is attributed to hold the largest market share, and the UK mild cognitive impairment market is projected be the fastest growing market in the Europe region.

The Asia-pacific mild cognitive impairment market is expected to be the fastest growing from 2024 to 2032 owing to high patient population, rising number of mild cognitive cases, and favorable regulatory policies. Moreover, key players working in the mild cognitive impairment market are actively expanding into this region, further driving the regional market growth. Moreover, China mild cognitive impairment market accounted to hold the largest market share, and the India mild cognitive impairment market is projected to be the fastest growing market in the Asia-Pacific region.

Mild Cognitive Impairment Market Key Market Players & Competitive Insights

The Mild Cognitive Impairment Market is distinguished by the presence of numerous regional and local players catering to mild cognitive impairment market products that are evolving at a rapid pace. Furthermore, the increasing burden of mild cognitive impairment across the globe and rising awareness associated with mild cognitive impairment in the healthcare industry is further driving the growth of Mild Cognitive Impairment Market during the forecast period. The major players have adopted a strategy of obtaining regulatory approval from government agencies for their products and signing contracts and agreements to broaden their reach.

Eisai Co., Ltd. manufactures prescription drugs and medical equipment and primarily sells to sales agents and subsidiaries. They aim to provide services for a risk prediction algorithm for early detection of mild cognitive impairment (MCI) and dementia.

In January 2023, Eisai Co., Ltd. (Japan) announced that the FDA granted accelerated approval to LEQEMBI (lecanemab-irmb), a treatment for early AD.

Key Companies mild cognitive impairment in market includes.

• Johnson & Johnson Services, Inc. (US)


• Pfizer Inc. (US)


• Novartis AG (Switzerland)


• AbbVie Inc. (US)


• Biogen (Switzerland)


• Eisai Co., Ltd. (Japan)


• Aurobindo Pharma (India)


• Sun Pharmaceutical Industries Ltd (India)


• Teva Pharmaceutical Industries Ltd. (Israel)


• Taj Pharmaceuticals Limited (India)

MILD COGNITIVE IMPAIRMENT Market Industry Developments

• January 2023, Biogen (US) announced that the FDA granted accelerated approval to LEQEMBI (lecanemab-irmb), a treatment for early AD developed in collaboration with Eisai Co., Ltd (Japan).

 Mild Cognitive Impairment Market Segmentation

 Mild Cognitive Impairment Disease Type Outlook

• Amnestic MCI


• Non-Amnestic MCI

Mild Cognitive Impairment Age Outlook

• Child


• Adult


• Geriatric

Mild Cognitive Impairment Indication Outlook

• Lewy Body Dementia


• Parkinson's Disease Dementia


• Alzheimer’s Disease


• Vascular Dementia


• Others

Mild Cognitive Impairment Treatment Outlook

• Medication
  
  
  
  • Cholinesterase Inhibitors
  
  
  • Benzodiazepines
  
  
  • Glutamate Inhibitors
  
  
  • Antihistamines
  
  
  • Mao Inhibitors
  
  
  • Proton Pump Inhibitors
  
  
  
  


• Therapy
  
  
  
  • Cognitive Stimulation Therapy
  
  
  • Cognitive Behavioural Therapy (CBT)
  
  
  
  

Mild Cognitive Impairment Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America